In this installment, we delve into one of the most debated scientific advancements of our time: CRISPR gene-editing ...

New research adds to our understanding of the function of the human genome. An international team of researchers has made ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

This important study reveals a role for IκBα in the regulation of embryonic stem cell pluripotency. The solid data in mouse embryonic stem cells include separation of function mutations in IκBα to ...

CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats. It is a component of bacterial immune systems that can cut DNA, and has been repurposed as a gene editing tool. CRISPR is ...

ChristianaCare’s Gene Editing Institute has secured a prominent place on The Scientist’s Top 10 Innovations list for 2024, ...

They applied the new method to more than 1,500 European genomes (a person's complete set of DNA) from people who lived primarily during the first millennium AD (year 1 to 1000), encompassing the ...

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks.

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other CRISPR stocks.